Andrew Hollman Meyer - 01 May 2025 Form 4 Insider Report for Janux Therapeutics, Inc. (JANX)

Role
Chief Business Officer
Signature
/s/ James Pennington, Attorney-in-Fact
Issuer symbol
JANX
Transactions as of
01 May 2025
Net transactions value
-$92,713
Form type
4
Filing time
02 May 2025, 20:00:06 UTC
Previous filing
23 Apr 2025
Next filing
30 Oct 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Meyer Andrew Hollman Chief Business Officer C/O JANUX THERAPEUTICS, INC., 10955 VISTA SORRENTO PARKWAY, SUITE 200, SAN DIEGO /s/ James Pennington, Attorney-in-Fact 02 May 2025 0001864159

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction JANX Common Stock Options Exercise $14,032 +3,333 +4.1% $4.21 85,472 01 May 2025 Direct
transaction JANX Common Stock Sale $93,703 -2,933 -3.4% $31.95 82,539 01 May 2025 Direct F1, F2
transaction JANX Common Stock Sale $13,041 -400 -0.48% $32.60 82,139 01 May 2025 Direct F1, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction JANX Stock Option (right to buy) Options Exercise $0 -3,333 -3.7% $0.000000 87,332 01 May 2025 Common Stock 3,333 $4.21 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 30, 2024.
F2 The weighted average sale price for the transaction reported was $31.9479 and the range of prices were between $31.44 and $32.38. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
F3 The weighted average sale price for the transaction reported was $32.6034 and the range of prices were between $32.52 and $33.66. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
F4 Immediately exercisable.